Chromatin/Epigenetics
Epigenetics is the heritable modifications in gene expression that is not associated with changes in DNA sequence. Epigenetic modifications occur mostly on DNA or on the histone octamer. There are several types of epigenetics modifications, DNA methylation by DNA-methyl transferase (DNMT) and covalent modification of histones (e.g. acetylation, methylation, phosphorylation and ubiquitination). Histone acetylation by histone acetyltransferases (HATs) is involved in transcriptional activation, whereas histone deacetylation by histone deacetylases (HDACs) is connected with transcriptional repression. Histone demethylation is associated with lysine-specific demethylase (LSD) and JmjC domain containing histone demethylase (JHDM).
The nucleosome is consisted of four histone proteins (H2A, H2B, H3, and H4), they are primary building block of chromatin. The addition and removal of specific chemical groups refers to as epigenetic marks, it regulates chromatin structure and affects gene expression. Moreover, RNA is intimately involved in the formation of a repressive chromatin state.
Epigenetic mechanism responds to environmental changes at the cellular level and thus influences cellular plasticity. Chromatin and epigenetic regulation play a significant role in the programming of the genome during development and stress response, defects in epigenetics can lead to cancer, inflammation and metabolic disorders etc.
-
A4511 CercosporamideTarget: JAK|MNKSummary: Mnk2 and JAK3 inhibitor
-
A4512 Cucurbitacin ITarget: STAT|JAKSummary: STAT3/JAK2 signaling inhibitor
-
A3741 Pyridone 6Target: JAKSummary: Pan-JAK inhibitor
-
B1130 GLPG06341 CitationTarget: JAKSummary: JAK1 inhibitor
-
A3937 XL019Target: JAKSummary: JAK2 inhibitor,potent and selective
-
A3012 Ruxolitinib (INCB018424)4 CitationTarget: JAKSummary: JAK inhibitor
-
A4135 Tofacitinib (CP-690550) Citrate2 CitationTarget: JAKSummary: Potent JAK inhibitor
-
A4136 TG101348 (SAR302503)2 CitationTarget: FLT3|JAK|c-RETSummary: JAK-2 inhibitor,potent and selective
-
A4137 AZD1480Target: JAKSummary: JAK2 inhibitor,ATP-competitive and novel
-
A4138 Tofacitinib (CP-690550,Tasocitinib)1 CitationTarget: JAKSummary: Janus kinase inhibitor